These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33044400)
1. A review of pediatric neuroendocrine tumors, their detection, and treatment by radioisotopes. Haddad T; Fard-Esfahani A; Vali R Nucl Med Commun; 2021 Jan; 42(1):21-31. PubMed ID: 33044400 [TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceuticals used for diagnosis and therapy of NETs. Papachristou M Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556 [TBL] [Abstract][Full Text] [Related]
4. Molecular Imaging and Therapy for Neuroendocrine Tumors. Desai H; Borges-Neto S; Wong TZ Curr Treat Options Oncol; 2019 Aug; 20(10):78. PubMed ID: 31468190 [TBL] [Abstract][Full Text] [Related]
5. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Kjaer A; Knigge U Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100 [TBL] [Abstract][Full Text] [Related]
6. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807 [TBL] [Abstract][Full Text] [Related]
8. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Harris PE; Zhernosekov K Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893 [TBL] [Abstract][Full Text] [Related]
9. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780 [TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455 [No Abstract] [Full Text] [Related]
12. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
13. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
14. Radionuclide Therapy for Neuroendocrine Tumors. Cives M; Strosberg J Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446 [TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. Wang L; Tang K; Zhang Q; Li H; Wen Z; Zhang H; Zhang H Biomed Res Int; 2013; 2013():102819. PubMed ID: 24106690 [TBL] [Abstract][Full Text] [Related]
16. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs. Bomanji JB; Papathanasiou ND Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626 [TBL] [Abstract][Full Text] [Related]
17. Tumor imaging and therapy using radiolabeled somatostatin analogues. de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476 [TBL] [Abstract][Full Text] [Related]
18. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. Patel M; Tena I; Jha A; Taieb D; Pacak K Front Endocrinol (Lausanne); 2021; 12():625312. PubMed ID: 33854479 [TBL] [Abstract][Full Text] [Related]